(function(){var loadHandler=window['sl_{ED6C3D53-6C22-4572-BCFE-45929BD6739B}'];loadHandler&&loadHandler(12, '<div id="spr0_9c6fe4"><div id="spr1_9c6fe4" class="kern"><img id="img2_9c6fe4" src="data/img1.png" width="1024px" height="768px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_9c6fe4" class="kern"><div id="spr3_9c6fe4"><img id="img0_9c6fe4" src="data/img8.png" width="1024" height="773" alt="http://wallpaper.konclip.com/wp-content/gallery/power-point-wk-84/power-point-theme-153.jpg" style="top:-0.011px;"/></div><div id="spr4_9c6fe4" style="left:730.133px;top:733.156px;"><div style="width:0px;"><span id="txt0_9c6fe4" class="nokern relpos" style="left:10.24px;top:3.321px;">Fabbri C, et al. WJG 2014;20:8424-8448</span></div></div><div id="spr5_9c6fe4" style="left:9.956px;top:180.089px;"><div style="width:0px;"><span id="txt1_9c6fe4" class="relpos" style="left:10.24px;top:7.211px;">Ref.             Design       no. of cases     technical success   clinical success  complication</span></div><div style="width:0px;"><span id="txt2_9c6fe4" class="relpos" style="left:10.24px;top:41.344px;">,yr                                                                      (SPDD)</span></div><div style="width:0px;"><span id="txt3_9c6fe4" class="relpos" style="left:10.24px;top:109.611px;">Will,2007        RS                 12                   100% (67%)                  50%                    43%</span></div><div style="width:0px;"><span id="txt4_9c6fe4" class="relpos" style="left:10.24px;top:143.744px;">Tessier,2007   RS                 36                     92% (92%)                  69%                    55%</span></div><div style="width:0px;"><span id="txt5_9c6fe4" class="relpos" style="left:10.24px;top:177.877px;">Kahaleh,2007RS                 13                   100% (77%)                  77%                    15%</span></div><div style="width:0px;"><span id="txt6_9c6fe4" class="relpos" style="left:10.24px;top:212.011px;">Barkay,2010   RS                 21                     86% (48%)                  86%                    10%</span></div><div style="width:0px;"><span id="txt7_9c6fe4" class="relpos" style="left:10.24px;top:246.144px;">Ergun, 2011    RS                 20                   100% (90%)                 72%                     20%</span></div><div style="width:0px;"><span id="txt8_9c6fe4" class="relpos" style="left:10.24px;top:280.277px;">Shah, 2012     RS                 25                   100% (93%)                100%                   16%</span></div><div style="width:0px;"><span id="txt9_9c6fe4" class="relpos" style="left:10.24px;top:314.411px;">Vila, 2012       RS                 19                     58% (NR)                    NR                       26%</span></div><div style="width:0px;"><span id="txt10_9c6fe4" class="relpos" style="left:10.24px;top:348.544px;">Kurihara,2013RS                14                   100% (93%)                  93%                      7%</span></div><div style="width:0px;"><span id="txt11_9c6fe4" class="relpos" style="left:10.24px;top:382.677px;">Fujii, 2013      RS                 45                     98% (73%)                  53%                     24%</span></div><div style="width:0px;"><span id="txt12_9c6fe4" class="relpos" style="left:10.24px;top:450.944px;">Total           9 studies        205               58-100%, 92.8%    53-100%,74.5%   7-55%,20%</span></div></div><div id="spr6_9c6fe4" style="left:9.956px;top:180.089px;"><div style="width:0px;"><span id="txt13_9c6fe4" class="relpos" style="left:10.24px;top:1.522px;">Ref.             Design       no. of cases     technical success   clinical success  complication</span></div><div style="width:0px;"><span id="txt14_9c6fe4" class="relpos" style="left:10.24px;top:35.655px;">,yr                                                                      (SPDD)</span></div><div style="width:0px;"><span id="txt15_9c6fe4" class="relpos" style="left:10.24px;top:103.922px;">Will,2007        RS                 12                   100% (67%)                  50%                    43%</span></div><div style="width:0px;"><span id="txt16_9c6fe4" class="relpos" style="left:10.24px;top:138.055px;">Tessier,2007   RS                 36                     92% (92%)                  69%                    55%</span></div><div style="width:0px;"><span id="txt17_9c6fe4" class="relpos" style="left:10.24px;top:172.188px;">Kahaleh,2007RS                 13                   100% (77%)                  77%                    15%</span></div><div style="width:0px;"><span id="txt18_9c6fe4" class="relpos" style="left:10.24px;top:206.322px;">Barkay,2010   RS                 21                     86% (48%)                  86%                    10%</span></div><div style="width:0px;"><span id="txt19_9c6fe4" class="relpos" style="left:10.24px;top:240.455px;">Ergun, 2011    RS                 20                   100% (90%)                 72%                     20%</span></div><div style="width:0px;"><span id="txt20_9c6fe4" class="relpos" style="left:10.24px;top:274.588px;">Shah, 2012     RS                 25                   100% (93%)                100%                   16%</span></div><div style="width:0px;"><span id="txt21_9c6fe4" class="relpos" style="left:10.24px;top:308.722px;">Vila, 2012       RS                 19                     58% (NR)                    NR                       26%</span></div><div style="width:0px;"><span id="txt22_9c6fe4" class="relpos" style="left:10.24px;top:342.855px;">Kurihara,2013RS                14                   100% (93%)                  93%                      7%</span></div><div style="width:0px;"><span id="txt23_9c6fe4" class="relpos" style="left:10.24px;top:376.988px;">Fujii, 2013      RS                 45                     98% (73%)                  53%                     24%</span></div><div style="width:0px;"><span id="txt24_9c6fe4" class="relpos" style="left:10.24px;top:445.255px;">Total           9 studies        205               58-100%, 92.8%    53-100%,74.5%   7-55%,20%</span></div></div><div id="spr7_9c6fe4" style="left:-46.044px;top:20.267px;"><div style="width:0px;"><span id="txt25_9c6fe4" class="relpos" style="left:201.556px;top:14.385px;">EUS-guided Pancreatic Duct Drainage</span></div><div style="width:0px;"><span id="txt26_9c6fe4" class="relpos" style="left:200px;top:12.83px;">EUS-guided Pancreatic Duct Drainage</span></div><div style="width:0px;"><span id="txt27_9c6fe4" class="relpos" style="left:136.693px;top:61.732px;">(Endo-Sonoscopic Pancreatic Duct Drainage: ESPD)</span></div><div style="width:0px;"><span id="txt28_9c6fe4" class="relpos" style="left:135.289px;top:60.328px;">(Endo-Sonoscopic Pancreatic Duct Drainage: ESPD)</span></div></div><div id="spr8_9c6fe4" style="left:-46.044px;top:20.267px;"><div style="width:0px;"><span id="txt29_9c6fe4" class="relpos" style="left:201.556px;top:8.696px;">EUS-guided Pancreatic Duct Drainage</span></div><div style="width:0px;"><span id="txt30_9c6fe4" class="relpos" style="left:200px;top:7.141px;">EUS-guided Pancreatic Duct Drainage</span></div><div style="width:0px;"><span id="txt31_9c6fe4" class="relpos" style="left:136.693px;top:56.043px;">(Endo-Sonoscopic Pancreatic Duct Drainage: ESPD)</span></div><div style="width:0px;"><span id="txt32_9c6fe4" class="relpos" style="left:135.289px;top:54.639px;">(Endo-Sonoscopic Pancreatic Duct Drainage: ESPD)</span></div></div><div id="spr9_9c6fe4" style="left:20.089px;top:666.844px;"><div style="width:0px;"><span id="txt33_9c6fe4" class="relpos" style="left:10.24px;top:8.29px;">RS: Retrospective study, SPDD: Successful pancreatic duct drainage, Complications: early &amp; late for procedure &amp; stent</span></div><div style="width:0px;"><span id="txt34_9c6fe4" class="relpos" style="left:10.24px;top:32.183px;">       related complication, such as bleeding pancreatitis, perforation, collection, pain.</span></div><div style="width:0px;"><span id="txt35_9c6fe4" class="relpos" style="left:10.24px;top:56.077px;">       NR: Not reported.</span></div></div><div id="spr10_9c6fe4" style="left:20.089px;top:666.844px;"><div style="width:0px;"><span id="txt36_9c6fe4" class="relpos" style="left:10.24px;top:2.601px;">RS: Retrospective study, SPDD: Successful pancreatic duct drainage, Complications: early &amp; late for procedure &amp; stent</span></div><div style="width:0px;"><span id="txt37_9c6fe4" class="relpos" style="left:10.24px;top:26.495px;">       related complication, such as bleeding pancreatitis, perforation, collection, pain.</span></div><div style="width:0px;"><span id="txt38_9c6fe4" class="relpos" style="left:10.24px;top:50.388px;">       NR: Not reported.</span></div></div><div id="spr11_9c6fe4" style="left:219px;top:120px;"><div style="width:0px;"><span id="txt39_9c6fe4" class="relpos" style="left:15.24px;top:12.186px;">Level of Evidence: III, case series</span></div></div><div id="spr12_9c6fe4" style="left:219px;top:120px;"><img id="img1_9c6fe4" src="data/img12.png" width="576" height="63" alt=""/></div><div id="spr13_9c6fe4" style="left:219px;top:120px;"><div style="width:0px;"><span id="txt40_9c6fe4" class="relpos" style="left:15.24px;top:6.497px;">Level of Evidence: III, case series</span></div></div></div></div>');})();